Francie Reintjes

Francie Reintjes is a seasoned professional in the life sciences investment sector, currently serving as Vice President of Growth Investments at Novo Holdings since May 2020, where expertise lies in investing in scalable, high-growth companies. Reintjes holds multiple board observer roles, including positions at Route 92 Medical, Evosep Biosystems, Kate Farms, and Invetx, the latter being a notable acquisition by Dechra for up to $520 million. Previous experience includes a founding team role at Incentrum Group, investment banking analysis at Bank of America Merrill Lynch, and internships at Verger Capital Management and Global Prairie. Francie Reintjes earned a Bachelor of Science in Mathematical Business from Wake Forest University.